[go: up one dir, main page]

CO5601024A2 - Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades causadas por protozoos - Google Patents

Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades causadas por protozoos

Info

Publication number
CO5601024A2
CO5601024A2 CO04070642A CO04070642A CO5601024A2 CO 5601024 A2 CO5601024 A2 CO 5601024A2 CO 04070642 A CO04070642 A CO 04070642A CO 04070642 A CO04070642 A CO 04070642A CO 5601024 A2 CO5601024 A2 CO 5601024A2
Authority
CO
Colombia
Prior art keywords
preventive treatment
miltefosine
active ingredient
use according
total daily
Prior art date
Application number
CO04070642A
Other languages
English (en)
Spanish (es)
Inventor
Jurgen Engel
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of CO5601024A2 publication Critical patent/CO5601024A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO04070642A 2002-01-25 2004-07-23 Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades causadas por protozoos CO5601024A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10203195A DE10203195A1 (de) 2002-01-25 2002-01-25 Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen

Publications (1)

Publication Number Publication Date
CO5601024A2 true CO5601024A2 (es) 2006-01-31

Family

ID=7713213

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04070642A CO5601024A2 (es) 2002-01-25 2004-07-23 Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades causadas por protozoos

Country Status (16)

Country Link
EP (1) EP1467742A1 (fr)
JP (1) JP2005515244A (fr)
CN (1) CN1622811A (fr)
AR (1) AR038224A1 (fr)
AU (1) AU2003236787B2 (fr)
BR (1) BR0307021A (fr)
CA (1) CA2470185A1 (fr)
CO (1) CO5601024A2 (fr)
DE (1) DE10203195A1 (fr)
IL (2) IL162492A0 (fr)
MX (1) MXPA04007193A (fr)
NZ (1) NZ548040A (fr)
PE (1) PE20030732A1 (fr)
TW (1) TWI339582B (fr)
WO (1) WO2003061669A1 (fr)
ZA (1) ZA200404690B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501545B1 (de) * 2005-02-23 2007-10-15 Obwaller Andreas Dr Reinigungsmittel für kontaktlinsen
EP1800684A1 (fr) * 2005-12-20 2007-06-27 Zentaris GmbH Nouveaux alkylphospholipides et leur utilisation
AU2006328479B2 (en) * 2005-12-19 2012-03-08 Aeterna Zentaris Gmbh Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132345A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US5985935A (en) * 1992-03-06 1999-11-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
EP1051159B1 (fr) * 1998-01-22 2002-04-10 Zentaris AG Compositions pharmaceutiques solides contenant miltefosine et servant a traiter la leishmaniose par administration orale
DE10020812C2 (de) * 2000-04-20 2003-06-26 Robert Koch Inst Verwendung von Naphthindazol-4,9-chinonen als Antiparasitika
WO2002036588A2 (fr) * 2000-11-06 2002-05-10 U.S. Army Medical Research And Materiel Command Amidines inversees et methodes d'utilisation pour traiter, prevenir, et inhiber la leishmaniose

Also Published As

Publication number Publication date
EP1467742A1 (fr) 2004-10-20
IL162492A (en) 2009-12-24
TW200302103A (en) 2003-08-01
ZA200404690B (en) 2004-09-27
CA2470185A1 (fr) 2003-07-31
WO2003061669A1 (fr) 2003-07-31
JP2005515244A (ja) 2005-05-26
IL162492A0 (en) 2005-11-20
AU2003236787B2 (en) 2007-03-22
PE20030732A1 (es) 2003-09-27
BR0307021A (pt) 2004-11-03
MXPA04007193A (es) 2004-10-29
AR038224A1 (es) 2005-01-05
CN1622811A (zh) 2005-06-01
TWI339582B (en) 2011-04-01
DE10203195A1 (de) 2003-08-07
NZ548040A (en) 2007-06-29

Similar Documents

Publication Publication Date Title
MXPA05002883A (es) Formas de dosis y terapias relacionadas.
CR9662A (es) Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
ES2141706T3 (es) Formulaciones y su empleo en el tratamiento de enfermedades neurologicas.
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
BRPI0413756A (pt) composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
AR046773A1 (es) Formulaciones farmaceuticas de bisfosfonatos
TR200102067T2 (tr) Topikal formülasyonların mukoza boşluğuna verilmesi için aplikatör
MXPA02012792A (es) Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos.
MXPA05003366A (es) Inhibidores de la proteina reguladora de conductancia transmembranal de la fibrosis quistica y usos de los mismos.
BR0104228A (pt) Derivados do ácido de alquilamino úteis como agentes farmacêuticos, método para fabricação de um composto, composição farmacêutica, métodos para tratamentos diversos e uso de um composto na fabricação de um medicamento para tratamentos diversos
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
AR037560A1 (es) Formulacion de altas dosis de ibandronato
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
AR033151A1 (es) Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
HUP0401672A2 (hu) Kis koncentrációjú peroxid alkalmazása hüvelyi fertőzések gyógyító vagy megelőző kezelésénél
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
ES2108014T3 (es) Composicion antiviral de 3'-azido-2',3'-dideoxi-5-metilcitidina.
CO5601024A2 (es) Uso de alquilfosfocolinas para el tratamiento preventivo de enfermedades causadas por protozoos
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica

Legal Events

Date Code Title Description
FC Application refused